

Genomic analysis of Mpox, functional characterization of hypothetical proteins and identification of potential inhibitors

Genomics 116 (2024) 110763

Contents lists available at ScienceDirect

Genomics

journal homepage: www.elsevier.com/locate/ygeno

ELSEVIER

Genome analysis of the mpox (formerly monkeypox) virus and characterization of core/variable regions

> Mol Divers. 2025 Apr;29(2):1589-1617. doi: 10.1007/s11030-024-10935-4. Epub 2024 Jul 24.

Functional characterization and structural prediction of hypothetical proteins in monkeypox virus and identification of potential inhibitors

Reana Raen ^{1, 2}, Muhammad Muinul Islam ³, Redwanul Islam ³, Md Rabiul Islam ⁴, Tanima Jarin ⁵

Affiliations + expand
PMID: 39043911 DOI: 10.1007/s11030-024-10935-4

FULL TEXT LINKS
SpringerLink
FULL-TEXT ARTICLE

ACTIONS
Cite
Collections
Permalink

Zwe Win Paing

2nd Year PhD

07.01.2026




One of the greatest achievement in **21 century** is **Smallpox** was declared **eradicated** by the WHO in 1980, however, it poses a threat to human as the disease could reappear due to accidental release of the viruses from repositories or intentional de novo synthesis of infectious viruses for bioterrorism.





Recent global transmission of endemic Mpox, along with cases of human-to-human transmission of poxviruses that belong in Orthopoxvirus, Molluscipoxvirus, and Parapoxvirus genera, indicates a potential for smallpox-like disease outbreaks.


Introduction

Geographical distribution of confirmed and suspected **monkeypox cases** during the outbreak between May and August 2022.






- Enveloped dsDNA virus
- Size: 220 Kb, 223 ORFs
- Genus: *Orthopoxvirus* genus
- Family: *Poxviridae*



ITR= Inverted terminal repeats

Introduction: Mpox transmission and outbreak



1st outbreak

- 1970
- Democratic Republic of Congo (Central African countries)
- Clade I

2nd outbreak


- 2003
- Western African countries
- Clade II

Current outbreak

- Clade III (hMpox-1 A, B.1, A.1.1, A.1, and A.2)

- Natural reservoir of mpox remains unidentified
- Transmitted to humans **through rodents and non-human primates**

Introduction



Genomics 116 (2024) 110763



Contents lists available at [ScienceDirect](#)

Genomics

journal homepage: www.elsevier.com/locate/ygeno

Genome analysis of the mpox (formerly monkeypox) virus and characterization of core/variable regions

Q2

Citation Score
8.1

Impact Factor
3.0

- Rational of the study:** To address the gaps in **multinational outbreak**, providing further insights into **evolutionary trajectory**, **genetic diversity and phenotypic traits** of the virus.
- Hypothesis:** Variable regions tend to have more mutations, gene changes, repeats, and recombination.
- Objective:** To identify and characterize the **core/variable regions** of the currently available Mpox virus whole genome sequences.



CNCB



Data Retrieving



Nextclade^{v3.13.1}

QC



Gene Annotation




NCVOGs



Orthofinder v2.5.2



Core-pan analysis



MCscan

Collinearity analysis



Gubbins v3.2.1
TRF and IRF
SNP-sites

Recombination analysis
Repeats sequences detection
SNP analysis


Objective: To assess the quality of the retrieved whole genome sequences

Total WGS: 853


Selected WGS: 825

Genome length ranged from 185,309 bp to 206,372 bp

GC content ranged from 32.80% to 33.12%



10.76%



0.97%

Objective: To see Mpox specific genes

Conserved regions: DNA replication, recombination, and repair, as well as virion structure and morphogenesis


Variable regions: Host-virus interaction

1st circle: Coding sequences (cds) of USA_2022_MA001

- Sense strand
- Antisense strand

2nd circle: functional categories



- Host-virus interactions
- Other metabolic functions
- Signal transduction regulation
- DNA replication, recombination and repair
- Nucleotide metabolism
- Virion structure and morphogenesis
- Transcription and RNA processing
- Mobile elements
- Uncharacterized



Mpox

Chodopoxviridae
Poxviridae

Ref Seq: USA_2022_MA001





The result showed that multi-copy and specific genes are generally located in the variable regions

Purple: Well-conserved genome collinearity between mpox interspecies


Blue: MPXV genome contains ITRs

The **ITRs** also lead to homology between the coding gene sequences at the beginning of the genome and the gene sequences at the end





Most of the recombination events occurred in the variable regions




Length of tandem repeat of MPXV within the IIb clade is overall lower than those in the other three clades

Average **SNP** density in variable regions is higher than in core regions

The average **SNP** density in variable regions (**16.16 ± 6.15 SNPs/Kb**) was significantly higher than that in core regions

The gene with the highest **SNP** density was Kelch repeat and BTB domain-containing protein 2 (**KBTBD2**)

Among all viruses, only the genomes of poxviruses contain genes for **kelch-like proteins**



- The mpox genome's core and variable regions were clearly delineated, with **recombination and repeat** sequences concentrated in **variable regions**.
- Single nucleotide polymorphisms (**SNPs**) are predominantly found in the **variable regions**, indicating higher genetic diversity there.
- **High SNP density** in the **KBTD2** gene may relate to host adaptation, warranting further experimental investigation.

> Mol Divers. 2025 Apr;29(2):1589-1617. doi: 10.1007/s11030-024-10935-4. Epub 2024 Jul 24.

Functional characterization and structural prediction of hypothetical proteins in monkeypox virus and identification of potential inhibitors

Reana Raen ^{1 2}, Muhammad Muinul Islam ³, Redwanul Islam ³, Md Rabiul Islam ⁴, Tanima Jarin ⁵

Affiliations + expand

PMID: 39043911 DOI: 10.1007/s11030-024-10935-4

FULL TEXT LINKS



ACTIONS

“ Cite


🔖 Collections

↩ Permalink

Q2

Citation Score
4.8

Impact Factor
3.9



Properties of Hypothetical Protein

Objective: To retrieve the hypothetical proteins and analyze the features of selected HP

GCF 000857045.1 was retrieved from NCBI database
191 proteins in the entire MPXV virus proteome including
28 HPs

Pfam, CDD-BLAST, ScanProsite, and SMART
 28 HPs were categorized into five group.

7 HPs are in high confidence level

AIE40426.1, MPXV-Congo_8-156 were in high confidence level



The CELLO program estimated the target protein's
 subcellular location as "Cytoplasmic"

Table 1 Specific physiochemical properties of the selected Hypothetical protein (MPXV-Congo_8-156)

Characteristics	Finding	Remark
Number of amino acids	503	Suitable
Molecular weight	57.35 kDa	Average
Theoretical pI	7.29	Slightly Basic
Chemical formula	$C_{2562}H_{3983}N_{687}O_{753}S_{28}$	–
Extinction coefficient (at 280 nm in H ₂ O)	76,960	–
Estimated half-life (mammalian reticulocytes)	30 h	–
Estimated half-life (yeast cell, in vivo)	> 20 h	–
Estimated half-life (E. coli, in vivo)	> 10 h	–
Instability index	39.01	Stable
Stable aliphatic index	82.27	Thermostable
Grand average hydropathicity (GRAVY)	– 0.350	Hydrophilic

Protein structure analysis

Objective: To predict the secondary and tertiary structure of HP



Secondary structure and tertiary structure of HP




Fig. 2 Analysis of protein phylogeny


Predictions from **NCBI-CD** search indicated the presence of a **PHA02782** superfamily domain

Table 2 3D Structure Generation with Different Servers


Webservers	Methodology	Accuracy
AlphaFold [62]	Neural network/Deep learning	70–75% [62]
I-Tasser (Iterative Threading ASSEm- bly Refinement) [63]	Multiple-threading alignments, ab initio, refine- ment	65–75% [63]
PDB (Protein Data Bank) [64]	Experimental data	60–70% [64]
ORION [65]	Machine learning, hybrid modeling	65–70% [65]
ESyPred3D [66]	Automated homology modeling	60–75% [66]
SWISS-MODEL [37]	Homology modeling	80–90% [37]

HP 3D structure matched 2D prediction and aligned with expected fold, suggesting similar function to its family proteins


Objective: To evaluate the accuracy of the anticipated three-dimensional structural model of the hypothetical protein



- 92.3% residues in most favored regions
- Remaining residues in additionally allowed regions
- No residues in disallowed regions
- Z-score of -6.79 for the model



(a)



(b)


Supports reliability of homology modeling

Model validation for HP

Active site determination

Objective: To analyze the tertiary configurations of protein and identify the binding pocket

Visualization of active sites CASTp server








Chain B contains stable, well-defined active sites, making it the primary target for docking and inhibitor design

VaxiJen score of 0.4911
Four conserved peptides passed the score



- Largest pocket: surface area 86.6 Å², volume 57.9 Å³
- Key residues in Chain B: TYR72, LEU73, GLN74, ILE75, VAL90, THR91, TYR92, ARG93, LYS95, TYR98, PRO190, ILE191, PRO192
- Chain B showed higher activity due to more stable binding sites
- Active residues align with PHA02782 superfamily domain

Docking of MPXV-Congo with drugs

Objective: To select the candidate ligands and preparation for docking



- Blide docking and site-specific docking with 500 compounds listed in Pubchem
- 5 lead phytochemicals selected (binding energies -9.2 to -8.8 kcal/mol) depending on docking scores, binding within active sites, and the manner of interactions



Conventional **Hydrogen Bond**, **Pi–Anion**, **Pi–Sigma**, **Pi–Alkyl** bonds were observed between AKOS001631077 and MPXV

Redocking, PK and Toxicity Analysis

Table 6 Binding Energies of Conventional Drugs

No.	Traditional compounds ID	Chemical name	Binding energy (Kcal/mol)
1	60,613	Cidofovir (Control)	− 5.2
2	483,477	Brincidofovir	− 5.5
3	16,124,688	Tecovirimat	− 4.1
4	135,398,740	Ganciclovir	− 5.1
5	54,682,461	Tipranavir	− 3.8

Displays the binding energies of the conventional medicines indicating lead phytochemicals exhibited stronger binding affinities to the target protein compared to the standard drugs

Table 7 Pharmacokinetics (ADMET) analysis of top drug compounds

	Absorption				Distribution		Metabolism	
	Water solubility (LogS)	GI Absorption	P-gp Substrate	Skin Permeation(cm/s)	BBB Permeation	Log VDss	CYP2D6 Inhib-itor	CYP2D6/CYP3A4 Substrate
Drug compounds								
Threshold value	≥ 0 Highly soluble; 0 to − 2 soluble; − 2 to − 4 moderately soluble	GI Absorption > 90 High		log Kp > 2.5 Low; log Kp < 2.5 High	BBB > 0.3 cross BBB, < 1 poorly dispersed to the BBB	VDSS: < 0.15 low distribution; VDss > 0.45 High tissue distribution of drug		
AKOS033625053	− 2.66	High	No	− 2.50	No	1.01	Yes	No
AKOS001631077	− 2.88	High	No	− 2.39	No	1.23	Yes	No
AKOS024581331	− 2.91	High	No	− 5.18	No	1.14	Yes	No
AKOS033624336	− 4.77	High	No	− 3.13	No	1.57	Yes	No
AKOS033706750	− 5.43	High	No	− 7.25	No	1.32	Yes	No

All the compounds have the good pharmacokinetic properties except of the compound 5 which has lower soluble activity in water and lower skin permeability.

Redocking, PK and Toxicity Analysis

Table 8 Lipophilicity, TPSA, Toxicity and Excretion Analysis of Top Drug Compounds

Drugs	(Log $P_{o/w}$)	TPSA (\AA^2)	Toxicity	PAINS	Lipinski rule Violation (5 rules were fulfilled)	Synthetic accessibility	Molecular weight (g/ mol)	Excretion Total clearance (log ml/min/kg)
AKOS033625053	3.05	98.31	No	0	No	3.42	453.4	0.65
AKOS001631077	1.51	112.14	No	0	No	3.17	395.4	0.43
AKOS024581331	2.21	119.33	No	0	No	3.31	385.4	0.48
AKOS033624336	2.07	112.18	No	0	No	3.10	479.4	0.46
AKOS033706750	1.54	120.38	Mild	0	No	3.05	453.4	0.47

Table 9 Inhibitory effects and Bioactivity (score from Molinspiration) of Top Drug Compounds

Natural compound	GPCR ligand	Ion channel modulator	Kinase inhibitor	Nuclear recep- tor ligand	Protease inhibitor	Enzyme inhibitor	Bioactiv- ity score
AKOS033625053	0.21	−0.08	−0.36	−0.01	0.09	0.05	0.16
AKOS001631077	0.04	−0.41	0.04	0.59	−0.17	0.34	0.34
AKOS024581331	0.11	−0.06	0.02	0.12	0.06	0.01	0.28
AKOS033624336	0.08	−0.03	0.01	0.09	0.04	0.02	0.38
AKOS033706750	0.02	−0.10	0.01	0.31	0.10	0.02	0.22

The selected drugs demonstrated significant efficacy in binding to G protein-coupled receptors (GPCRs) and displayed notable inhibitory effects on proteases and enzymes. Compound 1 and 2 were chosen for further analysis.

- **Integrated bioinformatics and computational approaches** effectively create and validate the protein model and identify active sites or binding pockets and identify potential antiviral compounds against MPXV.
- **Multiple drug candidates** demonstrated promising binding affinity, pharmacokinetic properties, and drug-likeness criteria.
- In silico analysis supports the **potential repurposing of existing drugs** as effective treatments for monkeypox.
- Highlights the value of combining **structural modeling, virtual screening, and simulation** in accelerated drug discovery.

Paper 1

Paper 2

Strong

Establish the bioinformatic workflows for the WGS analysis for the large DNA viruses with high divergent sequences

Use the varieties of comprehensive In-Silico tools to characterize and identify the hypothetical proteins, and screen the potential inhibitors

Weak

The key finding were not approved by laboratory experiment

Not clear how they select HP

Genomics

Identify the variants in highly diverse sequences in large DNA viruses

Properties analysis of the proteins

Advisor



Asst. Prof. Supranee Phanthanawiboon

SP lab Member



